{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:21:04Z","timestamp":1783524064783,"version":"3.55.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.tranon.2021.101022","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T21:17:37Z","timestamp":1612559857000},"page":"101022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6321-3562","authenticated-orcid":false,"given":"Juan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-6761","authenticated-orcid":false,"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101022_bib0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.seminoncol.2005.11.003","article-title":"Myelotoxicity from chemotherapy","volume":"33","author":"Daniel","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0002","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0003","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31 Pt 2","author":"Wu","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.tranon.2021.101022_bib0004","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3324\/haematol.2011.050799","article-title":"Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the intercontinental cooperative immune thrombocytopenia study group","volume":"96","author":"Kuhne","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2021.101022_bib0005","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0006","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.tranon.2021.101022_bib0007","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2014.118075","article-title":"T.s. investigators, Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis","volume":"100","author":"Stanworth","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2021.101022_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2009.01295.x","article-title":"Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?","volume":"99","author":"Schrezenmeier","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.tranon.2021.101022_bib0009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.seminhematol.2010.04.001","article-title":"Overview of platelet transfusion","volume":"47","author":"McCullough","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.tranon.2021.101022_bib0010","first-page":"547","article-title":"The role of platelets in tumor growth, metastasis, and immune evasion","author":"Zihai Li","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.tranon.2021.101022_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-immunol-042718-041607","article-title":"The platelet napoleon complex-small cells, but big immune regulatory functions","volume":"37","author":"Morrell","year":"2019","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.tranon.2021.101022_bib0012","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3389\/fimmu.2019.01320","article-title":"Regulation of Innate Immune Responses by Platelets","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.tranon.2021.101022_bib0013","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/vox.12443","article-title":"Effect of platelet storage time on platelet measurements: a systematic review and meta-analyses","volume":"111","author":"Caram-Deelder","year":"2016","journal-title":"Vox Sang"},{"key":"10.1016\/j.tranon.2021.101022_bib0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/trf.14401","article-title":"Storage time of platelet concentrates and risk of a positive blood culture: a nationwide cohort study","volume":"58","author":"Kreuger","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.tranon.2021.101022_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/vox.12013","article-title":"Impact of glucose and acetate on the characteristics of the platelet storage lesion in platelets suspended in additive solutions with minimal plasma","volume":"105","author":"Saunders","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.tranon.2021.101022_bib0016","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1111\/trf.15497","article-title":"Effect of storage of platelet concentrates in PAS-B, PAS-C, or plasma on transfusion reactions","volume":"59","author":"van Hout","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tranon.2021.101022_bib0017","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101022_bib0018","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1126\/science.283.5405.1183","article-title":"Reciprocal control of T helper cell and dendritic cell differentiation","volume":"283","author":"Rissoan","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.tranon.2021.101022_bib0019","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jss.2008.04.013","article-title":"The acellular fraction of stored platelets promotes tumor cell invasion","volume":"153","author":"Dineen","year":"2009","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0020","first-page":"6","article-title":"A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]","volume":"4","author":"Blumberg","year":"2004","journal-title":"BMC Blood Disord"},{"key":"10.1016\/j.tranon.2021.101022_bib0021","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","article-title":"Platelets increase the proliferation of ovarian cancer cells","volume":"120","author":"Cho","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0022","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.seminoncol.2014.04.006","article-title":"Platelets effects on tumor growth","volume":"41","author":"Goubran","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejim.2013.01.017","article-title":"The platelet-cancer loop","volume":"24","author":"Goubran","year":"2013","journal-title":"Eur. J. Intern Med."},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2021.101022_bib0024","first-page":"S13","article-title":"Platelets, inflammation and tissue regeneration","volume":"105","author":"Nurden","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2014-03-562538","article-title":"Paraneoplastic thrombocytosis: the secrets of tumor self-promotion","volume":"124","author":"Lin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0026","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1055\/s-0034-1370767","article-title":"Platelet-cancer interactions","volume":"40","author":"Goubran","year":"2014","journal-title":"Semin. Thromb Hemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0027","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2004.05352.x","article-title":"Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion","volume":"128","author":"Segal","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2021.101022_bib0028","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer: clinical practice guidelines of the American society of clinical oncology","volume":"19","author":"Schiffer","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0029","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia","volume":"17","author":"Adelborg","year":"2019","journal-title":"J. Thromb Haemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2165\/11594310-000000000-00000","article-title":"Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study","volume":"34","author":"Ten Berg","year":"2011","journal-title":"Drug Saf."},{"key":"10.1016\/j.tranon.2021.101022_bib0031","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1097\/MJT.0b013e31828232b8","article-title":"Same chemotherapy regimen leads to different myelotoxicity in different malignancies: a comparison of chemotherapy-associated myelotoxicity in patients with advanced ovarian and non-small-cell lung cancer","volume":"23","author":"Tas","year":"2016","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.tranon.2021.101022_bib0032","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00280-017-3289-6","article-title":"Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer","volume":"79","author":"Jang","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.tranon.2021.101022_bib0033","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1759-7714.12472","article-title":"Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: a retrospective analysis","volume":"8","author":"Ma","year":"2017","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0034","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0035","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0036","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ajco.12513","article-title":"An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer","volume":"12","author":"Wang","year":"2016","journal-title":"Asia Pac J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17474086.2020.1697226","article-title":"Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia","volume":"13","author":"Khan","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.tranon.2021.101022_bib0038","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2021.101022_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"issue":"23","key":"10.1016\/j.tranon.2021.101022_bib0040","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0041","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0042","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2019.00523","article-title":"Antigenic mimicry in paraneoplastic immune thrombocytopenia","volume":"10","author":"Vial","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2021.101022_bib0043","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.22211","article-title":"Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies","volume":"87","author":"Zeng","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2021.101022_bib0044","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/bloodadvances.2020001846","article-title":"Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia","volume":"4","author":"Shrestha","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2021.101022_bib0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2011.02.004","article-title":"Paraneoplastic autoimmune thrombocytopenia in solid tumors","volume":"81","author":"Krauth","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tranon.2021.101022_bib0046","doi-asserted-by":"crossref","first-page":"e13402","DOI":"10.1111\/ijcp.13402","article-title":"Efficacy of platelet-rich plasma for non-transfusion use: overview of systematic reviews","volume":"73","author":"Pachito","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.tranon.2021.101022_bib0047","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Lefrancais","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101022_bib0048","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet Transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2021.101022_bib0049","first-page":"809","article-title":"Platelet transfusion in hematology, oncology and surgery","volume":"111","author":"Wandt","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.tranon.2021.101022_bib0050","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2021.101022_bib0051","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Eng. J. Med."},{"key":"10.1016\/j.tranon.2021.101022_bib0052","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/asheducation-2015.1.462","article-title":"Platelet transfusion goals in oncology patients","volume":"2015","author":"Fasano","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.tranon.2021.101022_bib0053","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.0041-1132.2004.04118.x","article-title":"Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design","volume":"44","author":"Tinmouth","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tranon.2021.101022_bib0054","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2008-09-178236","article-title":"A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia","volume":"113","author":"Heddle","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/vox.12146","article-title":"Safety of platelet transfusion: past, present and future","volume":"107","author":"Katus","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.tranon.2021.101022_bib0056","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/vox.12039","article-title":"Growth factor release from platelet concentrates: analytic quantification and characterization for clinical applications","volume":"105","author":"Durante","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.tranon.2021.101022_bib0057","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tracli.2012.02.003","article-title":"CD40 ligand (CD154) involvement in platelet transfusion reactions","volume":"19","author":"Sahler","year":"2012","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tranon.2021.101022_bib0058","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12917-020-2254-5","article-title":"Quality control in veterinary blood banks: evaluation of canine platelet concentrates stored for five days","volume":"16","author":"Lasta","year":"2020","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.tranon.2021.101022_bib0059","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.blre.2014.04.002","article-title":"Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine","volume":"28","author":"Burnouf","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.tranon.2021.101022_bib0060","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.transci.2015.10.014","article-title":"Platelet microparticles and cancer: an intimate cross-talk","volume":"53","author":"Goubran","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tranon.2021.101022_bib0061","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood.V79.2.527.527","article-title":"Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates","volume":"79","author":"O'Connell","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0062","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1537-2995.1978.18478251236.x","article-title":"Temporary suppression of circulating antiplatelet alloantibodies by the massive infusion of fresh, stored, or lyophilized platelets","volume":"18","author":"Nagasawa","year":"1978","journal-title":"Transfusion"},{"key":"10.1016\/j.tranon.2021.101022_bib0063","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/026921639500900405","article-title":"Blood transfusion and its benefits in palliative care","volume":"9","author":"Gleeson","year":"1995","journal-title":"Palliat Med."},{"key":"10.1016\/j.tranon.2021.101022_bib0064","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/NAN.0b013e3181cfd392","article-title":"Refractory response to platelet transfusion therapy","volume":"33","author":"Eisenberg","year":"2010","journal-title":"J. Infus. Nurs."},{"key":"10.1016\/j.tranon.2021.101022_bib0065","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","article-title":"Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the US preventive services task force","volume":"164","author":"Chubak","year":"2016","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.tranon.2021.101022_bib0066","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0067","doi-asserted-by":"crossref","first-page":"636","DOI":"10.7326\/0003-4819-95-5-636","article-title":"Role of platelets in tumor cell metastases","volume":"95","author":"Karpatkin","year":"1981","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.tranon.2021.101022_bib0068","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.thromres.2019.02.026","article-title":"Multifaceted role of cancer educated platelets in survival of cancer cells","volume":"177","author":"Asghar","year":"2019","journal-title":"Thromb Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0069","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10637-012-9857-z","article-title":"A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Hudes","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.tranon.2021.101022_bib0070","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tranon.2021.101022_bib0071","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJM200406103502420","article-title":"Thrombocytosis","volume":"350","author":"Cheung","year":"2004","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.tranon.2021.101022_bib0072","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/ijc.27441","article-title":"Tumor-platelet interaction in solid tumors","volume":"130","author":"Buergy","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0073","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cpt.1066","article-title":"Modeling and simulation support eltrombopag dosing in pediatric patients with immune thrombocytopenia","volume":"104","author":"Wire","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tranon.2021.101022_bib0074","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0075","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The platelet lifeline to cancer: challenges and opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2021.101022_bib0076","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","article-title":"Interleukin-6 as a therapeutic target in human ovarian cancer","volume":"17","author":"Coward","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0077","doi-asserted-by":"crossref","first-page":"139","DOI":"10.7314\/APJCP.2014.15.1.139","article-title":"Elevated platelets enhance cancer cell migration, promote hematogenous metastasis and associate with a poor prognosis in advanced non-small cell lung cancer cases","volume":"15","author":"Li","year":"2014","journal-title":"Asian Pac J. Cancer Prev."},{"key":"10.1016\/j.tranon.2021.101022_bib0078","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in vivo","volume":"108","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0079","doi-asserted-by":"crossref","first-page":"e26125","DOI":"10.1371\/journal.pone.0026125","article-title":"Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells","volume":"6","author":"Egan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2021.101022_bib0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood-2013-03-492447","article-title":"A novel and essential role for FcgammaRIIa in cancer cell-induced platelet activation","volume":"123","author":"Mitrugno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0081","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2007-09-113837","article-title":"Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released","volume":"111","author":"Italiano","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0082","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-3083.1991.tb02522.x","article-title":"Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms","volume":"33","author":"Gersuk","year":"1991","journal-title":"Scand J. Immunol."},{"key":"10.1016\/j.tranon.2021.101022_bib0083","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2013-02-485011","article-title":"Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response","volume":"123","author":"Battinelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0084","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","article-title":"Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor","volume":"24","author":"Schumacher","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2021.101022_bib0085","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2021.101022_bib0086","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2013.06.020","article-title":"Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population","volume":"132","author":"Kim","year":"2013","journal-title":"Thromb Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0087","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10585-018-9874-1","article-title":"Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer","volume":"35","author":"Gareau","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.tranon.2021.101022_bib0088","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2021.101022_bib0089","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1172\/JCI85086","article-title":"FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal","volume":"126","author":"Haemmerle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2021.101022_bib0090","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1073\/pnas.261704098","article-title":"Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis","volume":"99","author":"Borsig","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.tranon.2021.101022_bib0091","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0092","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cellsig.2018.11.004","article-title":"How do chemokines navigate neutrophils to the target site: dissecting the structural mechanisms and signaling pathways","volume":"54","author":"Rajarathnam","year":"2019","journal-title":"Cell Signal"},{"key":"10.1016\/j.tranon.2021.101022_bib0093","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jnci\/dju363","article-title":"Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells","volume":"107","author":"Mrizak","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2021.101022_bib0094","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1615\/CritRevImmunol.v30.i5.30","article-title":"Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression","volume":"30","author":"Mailloux","year":"2010","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.tranon.2021.101022_bib0095","first-page":"4626","article-title":"Expression and clinical significance of SLP-2 in ovarian tumors","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2021.101022_bib0096","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1538-7836.2011.04318.x","article-title":"Tissue factor and cell signalling in cancer progression and thrombosis","volume":"9","author":"Ruf","year":"2011","journal-title":"J. Thromb Haemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0097","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130057","article-title":"Activation of blood coagulation in cancer: implications for tumour progression","volume":"33","author":"Lima","year":"2013","journal-title":"Biosci Rep"},{"key":"10.1016\/j.tranon.2021.101022_bib0098","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0099","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","article-title":"Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer","volume":"6","author":"Khorana","year":"2008","journal-title":"J. Thromb Haemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0100","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.6279","article-title":"Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer","volume":"7","author":"Nilsson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2021.101022_bib0101","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1182\/blood-2011-03-344408","article-title":"Blood platelets contain tumor-derived RNA biomarkers","volume":"118","author":"Nilsson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0102","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2017.09.019","article-title":"Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms","volume":"159","author":"Gomes","year":"2017","journal-title":"Thromb Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0103","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0030-1267042","article-title":"Platelet- and megakaryocyte-derived microparticles","volume":"36","author":"Flaumenhaft","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0104","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2141.1967.tb08741.x","article-title":"The nature and significance of platelet products in human plasma","volume":"13","author":"Wolf","year":"1967","journal-title":"Br J. Haematol."},{"key":"10.1016\/j.tranon.2021.101022_bib0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood-2009-01-200345","article-title":"Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function","volume":"114","author":"Schoenwaelder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0106","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1074\/jbc.M111.269811","article-title":"Engagement of alphaIIbbeta3 (GPIIb\/IIIa) with alphanubeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis","volume":"287","author":"Lonsdorf","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2021.101022_bib0107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0108","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1373\/clinchem.2005.057414","article-title":"P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction","volume":"52","author":"van der Zee","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tranon.2021.101022_bib0109","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.165.3.1259","article-title":"Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface","volume":"165","author":"Denzer","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2021.101022_bib0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-015-0327-z","article-title":"MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3","volume":"14","author":"Liang","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.16803","article-title":"Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model","volume":"7","author":"Guo","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2021.101022_bib0112","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0301-472X(02)00791-9","article-title":"Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells","volume":"30","author":"Baj-Krzyworzeka","year":"2002","journal-title":"Exp Hematol."},{"key":"10.1016\/j.tranon.2021.101022_bib0113","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ijc.20657","article-title":"Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer","volume":"113","author":"Janowska-Wieczorek","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0114","doi-asserted-by":"crossref","first-page":"828","DOI":"10.7150\/ijbs.19776","article-title":"Platelet-derived extracellular vesicles: an emerging therapeutic approach","volume":"13","author":"Tao","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tranon.2021.101022_bib0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.transci.2014.12.015","article-title":"Platelet microparticle: a sensitive physiological \"fine tuning\" balancing factor in health and disease","volume":"52","author":"Goubran","year":"2015","journal-title":"Transfus Apher Sci."},{"key":"10.1016\/j.tranon.2021.101022_bib0116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.transci.2015.10.010","article-title":"An overview of the role of microparticles\/microvesicles in blood components: are they clinically beneficial or harmful?","volume":"53","author":"Burnouf","year":"2015","journal-title":"Transfus Apher Sci."},{"key":"10.1016\/j.tranon.2021.101022_bib0117","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.thromres.2013.08.021","article-title":"Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y(1) and P2Y(1)(2) receptors","volume":"132","author":"Aslam","year":"2013","journal-title":"Thromb Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0118","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/ATVBAHA.118.311758","article-title":"Selective inhibition of PAR4 (protease-activated receptor 4)-mediated platelet activation by a synthetic nonanticoagulant heparin analog","volume":"39","author":"Lin","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tranon.2021.101022_bib0119","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/bjc.2017.214","article-title":"Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling","volume":"117","author":"Jiang","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101022_bib0120","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1038\/ncomms6256","article-title":"Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein","volume":"5","author":"Yu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2021.101022_bib0121","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41467-017-00411-z","article-title":"Platelets reduce anoikis and promote metastasis by activating YAP1 signaling","volume":"8","author":"Haemmerle","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2021.101022_bib0122","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2013.03.004","article-title":"Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies","volume":"162","author":"Paul","year":"2013","journal-title":"Transl Res."},{"key":"10.1016\/j.tranon.2021.101022_bib0123","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09537101003718065","article-title":"The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function","volume":"21","author":"Iyu","year":"2010","journal-title":"Platelets"},{"key":"10.1016\/j.tranon.2021.101022_bib0124","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0037-1604090","article-title":"Platelet CLEC-2: Roles Beyond Hemostasis","volume":"44","author":"Suzuki-Inoue","year":"2018","journal-title":"Semin. Thromb Hemost"},{"key":"10.1016\/j.tranon.2021.101022_bib0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature12501","article-title":"Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2","volume":"502","author":"Herzog","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2021.101022_bib0126","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10585-016-9826-6","article-title":"Melanoma cell metastasis via P-selectin-mediated activation of acid sphingomyelinase in platelets","volume":"34","author":"Becker","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.tranon.2021.101022_bib0127","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1349-7006.2012.02200.x","article-title":"Thromboxane A(2) receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells","volume":"103","author":"Matsui","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2021.101022_bib0128","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nri2956","article-title":"Platelets and the immune continuum","volume":"11","author":"Semple","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2021.101022_bib0129","doi-asserted-by":"crossref","first-page":"58322","DOI":"10.18632\/oncotarget.16871","article-title":"Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2021.101022_bib0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biomaterials.2015.10.046","article-title":"Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles","volume":"76","author":"Li","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.tranon.2021.101022_bib0131","article-title":"PD-1 blockade cellular vesicles for cancer immunotherapy","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tranon.2021.101022_bib0132","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.7150\/thno.19017","article-title":"Bioengineering of artificial antigen presenting cells and lymphoid organs","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2021.101022_bib0133","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41551-018-0310-2","article-title":"Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy","volume":"2","author":"Hu","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.tranon.2021.101022_bib0134","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5898","article-title":"Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models","volume":"11","author":"Papa","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tranon.2021.101022_bib0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2016-01-636399","article-title":"Metastasis: new functional implications of platelets and megakaryocytes","volume":"128","author":"Leblanc","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0136","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1073\/pnas.0510412103","article-title":"Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage","volume":"103","author":"Kisucka","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2021.101022_bib0137","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood-2011-02-334524","article-title":"Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis","volume":"118","author":"Battinelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101022_bib0138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/09537104.2013.872772","article-title":"Quality assessment of platelets stored in a modified platelet additive solution with trehalose at low temperature (10 degrees C) and in vivo effects on rabbit model of thrombocytopenia","volume":"26","author":"Wang","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.tranon.2021.101022_bib0139","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/09537104.2018.1447658","article-title":"A comprehensive proteomics study on platelet concentrates: platelet proteome, storage time and Mirasol pathogen reduction technology","volume":"30","author":"Salunkhe","year":"2019","journal-title":"Platelets"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:39:29Z","timestamp":1761835169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":139,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1936523321000140"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101022","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101022"}}